Pharmaceuticals

Dupixent Proven Effective in Treating Chronic Obstructive Pulmonary Disease and Asthma

bexib
By bexib 0 Min Read

Results from the Phase 3 BOREAS and NOTUS trials showed that Dupixent reduced moderate to severe COPD exacerbations by 31% over 52 weeks.

You Might Also Like

FDA Approves Incyte and Syndax Pharmaceuticals’ Nictimvo for Chronic Graft-Versus-Host Disease

A big bet, a bold step

Big Pharma leaders balance affordability and access as IRAs and supply constraints grow

CVS Health issues statement regarding Hurricane Debbie

HitGen Announces Partnership with Bridge Biotherapeutics

Share This Article
Previous Article 2:00PM Water Cooler 8/26/2024 | naked capitalism
Next Article Lifetime Show Spotlights Military Veterans Finding New Careers at U.S. Steel
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Within the city’s cloud migration strategy
Banking
Allstate that sells group health business nationwide
Insurance
Business clients require banks for Fednow and RTP functions
Banking
Blue Photo of 2025: Solo -industrial resilience means economic and national security.
Manufacturing